MCI-225, formerly known as AA-10021; AA-10025; AA-10026; DDP-225, is a norepinephrine reuptake/5-HT3/5-HT reuptake inhibitor potentially for the treatment of irritable. MCI-225 enhances attentional eye tracking in midpontine pretrigeminal preparation. MCI-225 could be effective in the treatment of senile dementia of the Alzheimer type, which is accompanied with both deficit in the BF-cortex cholinergic neuron and cerebral glucose hypometabolism. References: Eguchi J, Inomata Y, Saito K. The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism. Pharmacol Biochem Behav. 2001 Apr;68(4):677-83. PubMed PMID: 11526964.

纯度：≥98%

CAS：476148-82-0